By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Boehringer Ingelheim Corporation 

P.O. Box 368
900 Ridgebury Road
Ridgefield  Connecticut  06877-0368  U.S.A.
Phone: 203-798-99-88 Fax: 203-791-62-34


SEARCH JOBS








Company News
Boehringer Ingelheim Release: SPIRIVA RESPIMAT Now Available In The U.S. For Maintenance Treatment Of Asthma In Adults And Adolescents 2/4/2016 10:30:09 AM
Frost & Sullivan Lauds Boehringer Ingelheim for Bringing a Legacy of Excellence to Operational and Technological Processes in the Biopharmaceuticals Space 2/3/2016 9:29:03 AM
Boehringer Ingelheim Release: SPIRIVA RESPIMAT Now Available In The U.S. For Maintenance Treatment Of Asthma In Adults And Adolescents 2/3/2016 6:13:23 AM
Ablynx (ABLYF) To Receive €8 Million Milestone As Boehringer Ingelheim Starts First Patient Study With A Bi-Specific Nanobody In Oncology 1/29/2016 8:55:35 AM
Boehringer Ingelheim Release: Idiopathic Pulmonary Fibrosis (IPF): OFEV (Nintedanib) Is Recommended For Use Within The NHS By The National Institute For Health And Care Excellence (NICE) 1/27/2016 10:27:25 AM
Boehringer Ingelheim's Gilotrif (afatinib) Demonstrated Superiority To Iressa (gefitinib) In Reducing The Risk Of Disease Progression And Treatment Failure In First-Line Treatment Of Patients With EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer 1/27/2016 6:12:33 AM
Boehringer Ingelheim And Arena (ARNA) Collaborate To Advance Research In Schizophrenia 1/13/2016 10:19:42 AM
Arena (ARNA) Scores a $262 Million Schizophrenia Deal with Boehringer Ingelheim 1/13/2016 5:59:58 AM
Boehringer Ingelheim Release: Type 2 Diabetes: All Wales Medicines Strategy Group Recommends Jardiance (Empagliflozin) As An Option For Patients With Type 2 Diabetes In Wales 1/12/2016 12:23:28 PM
Boehringer Ingelheim Plans to Add More than 400 jobs in its Vienna Expansion 12/22/2015 9:08:17 AM
12345678910...
//-->